Skip to main content
SpringerLink
Log in

Ausweitung der Infusionsintervalle von Natalizumab senkt PML-Risiko

  • Literatur kompakt
  • Published:
DNP - Der Neurologe & Psychiater Aims and scope

An Erratum to this article was published on 05 June 2020

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 05 June 2020

    DNP - Der Neurologe & Psychiater 2020;21(2):15-6 Auf S. 15, letzter Absatz, und S. 16, erster Absatz, wurde die Zeitdauer der Natalizumab-Gabe einer Studie fehlerhaft angegeben. Korrekt ist: "Das kumulative Risiko, unter Natalizumab an einer PML zu erkranken, fand sich in allen drei Analyseansätz...

Author information

Authors and Affiliations

  1. Caritas Krankenhaus Bad Mergentheim, Uhlandstraße 7, 97980, Bad Mergentheim, Deutschland

    Mathias Buttmann

  2. Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Deutschland

    Axel Haarmann

Authors
  1. Mathias Buttmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel Haarmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buttmann, M., Haarmann, A. Ausweitung der Infusionsintervalle von Natalizumab senkt PML-Risiko. DNP 21, 15–16 (2020). https://doi.org/10.1007/s15202-020-2812-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15202-020-2812-5

Search

Navigation